Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3077218 13 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Early and Very Early GRIM19 and MCL1 Expression Are Correlated to Late Acquired Prednisolone Effects in a T-Cell Acute Leukemia Cell Line
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Glucocorticoids (GCs) are still first-line drugs for the treatment of childhood acute lymphoblastic leukemia (ALL). Prednisolone is a corticosteroid and one of the most important agents in the treatment of ALL. We report here a study of Prednisolone treatment using as a model a leukemia cell line with subsequent investigation of resistance-related gene expression. Gene silencing has been used in order to identify significant targets of resistance to GC-induced apoptosis in ALL cells. We analyzed effects of increasing doses of Prednisolone on ALL cell survival and growth, and we monitored immediate effects on gene expression through gene expression assays. We determined Prednisolone cytotoxicity and cell cycle distribution as well as DNA content. Upon treatment with escalating Prednisolone concentration, we observed a gradual decline in cell survival. MCL1 and GRIM19 were investigated as possible genes for the intrinsic capacity of this cell line to respond to corticosteroid and a snapshot of early changes was examined. Early MCL1 and GRIM19 expression correlated significantly to late GC-induced apoptosis. Prednisolone competitively induces MCL1 expression. Consistently with previous studies on primary leukemia blasts, cells are sensitive to proteasome inhibitor MG132; no interference of Prednisolone with MG132 effects on this cell line was noted. The inherent plasticity of clinically evolving cancer justifies approaches to characterize and prevent undesirable activation of early oncogenic pathways. Study of the pattern of intracellular signal pathway activation by anticancer drugs can lead to development of efficient treatment strategies by reducing detrimental secondary effects. © 2021, The Author(s), under exclusive license to Springer Nature Switzerland AG.
Έτος δημοσίευσης:
2021
Συγγραφείς:
G, L.
Adamaki, M.
Hatziagapiou, K.
Geronikolou, S.A.
Tsartsalis, A.N.
Vlahopoulos, S.
Περιοδικό:
Advances in Experimental Medicine and Biology
Εκδότης:
Springer-Verlag
Τόμος:
1339
Σελίδες:
147-160
Λέξεις-κλειδιά:
MCL1 protein, human; prednisolone; protein mcl 1, acute lymphoblastic leukemia; apoptosis; cell line; drug resistance; genetics; human; T lymphocyte; tumor cell line, Apoptosis; Cell Line; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; T-Lymphocytes
Επίσημο URL (Εκδότης):
DOI:
10.1007/978-3-030-78787-5_20
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.